Rebound lymphocytosis in a patient with chronic lymphocytic leukemia after cessation of a CDK 4/6 inhibitor for concomitant breast cancer.
Kimberley DoucetteCatherine E LaiPaula R PohlmannPublished in: The breast journal (2020)
Herein, we present the case of a female with co-occurring chronic lymphocytic leukemia (CLL) and metastatic ER/PR-positive breast cancer, who when taken off palbociclib for severe neutropenia and infectious complications, experienced rebound lymphocytosis. Though this was ultimately a benign clinical outcome, it exemplifies how CDK4/6 inhibitors induce a cell cycle arrest by decreasing the proliferation of hematopoietic stem cells (HSC), in this case CLL cells, with recovery of counts once drug is stopped.
Keyphrases
- chronic lymphocytic leukemia
- cell cycle arrest
- positive breast cancer
- cell death
- pi k akt
- stem cells
- signaling pathway
- cell cycle
- induced apoptosis
- squamous cell carcinoma
- case report
- small cell lung cancer
- bone marrow
- early onset
- risk factors
- emergency department
- drug induced
- cell proliferation
- estrogen receptor
- endoplasmic reticulum
- adverse drug
- oxidative stress
- mesenchymal stem cells
- young adults
- chemotherapy induced